Fibroblasts and endothelial cells interplay drives hypertrophic scar formation: Insights from in vitro and in vivo models.
Yaxin TanMengde ZhangYi KongFanliang ZhangYuzhen WangYuyan HuangWei SongZhao LiLinhao HouLiting LiangXu GuoQinghua LiuYu FengChao ZhangXiaobing FuSha HuangPublished in: Bioengineering & translational medicine (2023)
Hypertrophic scar formation is influenced by the intricate interplay between fibroblasts and endothelial cells. In this study, we investigated this relationship using in vitro and in vivo models. Clinical observations revealed distinct morphological changes and increased vascularity at pathological scar sites. Further analysis using OCTA, immunohistochemistry, and immunofluorescence confirmed the involvement of angiogenesis in scar formation. Our indirect co-culture systems demonstrated that endothelial cells enhance the proliferation and migration of fibroblasts through the secretion of cytokines including VEGF, PDGF, bFGF, and TGF-β. Additionally, a suspended co-culture multicellular spheroid model revealed molecular-level changes associated with extracellular matrix remodeling, cellular behaviors, inflammatory response, and pro-angiogenic activity. Furthermore, KEGG pathway analysis identified the involvement of TGF-β, IL-17, Wnt, Notch, PI3K-Akt, and MAPK pathways in regulating fibroblasts activity. These findings underscore the critical role of fibroblasts-endothelial cells crosstalk in scar formation and provide potential targets for therapeutic intervention. Understanding the molecular mechanisms underlying this interplay holds promise for the development of innovative approaches to treat tissue injuries and diseases.
Keyphrases
- endothelial cells
- extracellular matrix
- pi k akt
- high glucose
- signaling pathway
- vascular endothelial growth factor
- inflammatory response
- cell proliferation
- wound healing
- randomized controlled trial
- transforming growth factor
- stem cells
- cell cycle arrest
- risk assessment
- single molecule
- vascular smooth muscle cells
- epithelial mesenchymal transition
- angiotensin ii